ArticleCancer medicine2020
Differences in the preferential location and invasiveness of diffuse low-grade gliomas and their impact on outcome.
Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 19 citations in OpenAlex.
- Spatial analysis reveals the evolving organization of IDH-mutant glioma.Cancer cell · 2026Article
- Article
- Data-driven probabilistic mapping of the spatial and molecular landscape of glioma.Brain communications · 2026Article
- A white matter-centered approach to investigate recurrence pathways in high-grade gliomas: a single-center retrospective study.Journal of neuro-oncology · 2025Article
- Subcortical Brain Regions Associated With Seizure Risk in Patients With IDH Mutated Diffuse Gliomas.Brain and behavior · 2025Article
- Imaging features and consideration of progression pattern of diffuse hemispheric gliomas, H3 G34-mutant.Acta neuropathologica communications · 2025Article
- Diffuse gliomas: insights into clinical and histopathological features and survival rates from two centers in a middle-income country.Frontiers in oncology · 2025Article
- Unravelling differences and hallmarks in suspected diffuse low-grade gliomas: a multicentre database study.Brain communications · 2025Article
- Low-grade gliomas do not grow along white matter tracts: evidence from quantitative imaging.Brain communications · 2025Article
- Functional and oncological outcomes following more than three consecutive surgical resections for multiple relapses of initially grade 2 IDH-mutated gliomas.Acta neurochirurgica · 2024Article
- Qualitative and Visual Along-Tract Analysis of Diffusion-Based Parameters in Patients with Diffuse Gliomas.Brain sciences · 2024Article
- Anatomical and subcortical invasiveness in diffuse low-grade astrocytomas differ between IDH status and provide prognostic information.Upsala journal of medical sciences · 2024Article
- Connectomic insights into the impact of 1p/19q co-deletion in dominant hemisphere insular glioma patients.Frontiers in neuroscience · 2024Article
- Long-term follow up of patients with WHO grade 2 oligodendroglioma.Journal of neuro-oncology · 2023Article
- Editorial: Investigating the gliomas/white matter interplay and its implications for multidisciplinary treatment: State of art and future perspectives.Frontiers in neuroscience · 2022Article
- Role of Preoperative Assessment in Predicting Tumor-Induced Plasticity in Patients with Diffuse Gliomas.Journal of clinical medicine · 2021Article
- Lower-Grade Gliomas: An Epidemiological Voxel-Based Analysis of Location and Proximity to Eloquent Regions.Frontiers in oncology · 2021Article
- The link between gliomas infiltration and white matter architecture investigated with electron microscopy and diffusion tensor imaging.NeuroImage. Clinical · 2021Article
- Differences in the preferential location and invasiveness of diffuse low-grade gliomas and their impact on outcome.Cancer medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow-grade gliomas (LGGs) are primary diffuse slow-growing brain tumors derived from glial cells. The management of these tumors is dependent on their location, which often harbors eloquent areas. We retrospectively recorded the location of diffuse gliomas to identify whether specific differences exist between the histological types.
methodsWe analyzed 102 patients with previous histological diagnosis of WHO-II astrocytomas (62) and WHO-II oligodendrogliomas (40) according to WHO-2016 classification. MRI sequences (T2-FLAIR) were used for tumor volume segmentation and to create a frequency map of their locations within the Montreal Neurological Institute (MNI) space. The Brain-Grid (BG) system (standardized radiological tool of intersected lines according to anatomical landmarks) was created and merged with a tractography atlas for infiltration analysis.
resultsAstrocytomas frequently infiltrated association and projection white matter pathways within fronto-temporo-insular regions on the left side. Oligodendrogliomas infiltrated larger white matter networks (association-commissural-projection) of the frontal lobe bilaterally. A critical number of infiltrated BG voxels (7 for astrocytomas, 10 for oligodendrogliomas) significantly predicted shorter overall survival (OS) in both groups. Bilateral tumor extension in astrocytomas and preoperative tumor volume in oligodendrogliomas were independent prognostic factors for shorter OS.
conclusionsAstrocytomas and oligodendrogliomas differ in preferential location, and this has an impact on the type and the extent of white matter involvement. The number of BG voxels infiltrated reflected different tumor invasiveness and its impact on OS in both groups. All this new information may be valuable in neurosurgical oncology to classify and plan treatment for patients with diffuse gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.